NCT06252454View on ClinicalTrials.gov

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Dyspnea
Interventions
DRUG

Furosemide 40 mg

Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.

DRUG

Levodropropizine

Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation

OTHER

Placebo - saline

Placebo will be used as a comparator

Trial Locations (1)

50005

RECRUITING

Plicní klinika, Fakultni nemocnice Hradec Kralove, Hradec Králové

All Listed Sponsors
collaborator

Masaryk University

OTHER

lead

University Hospital Hradec Kralove

OTHER